A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 7, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

ASTX727

Given by PO

DRUG

Venetoclax

Given by PO

Trial Locations (1)

RECRUITING

MD Anderson Cancer Center, Houston